The awareness on, and prevalence of, Actinobacilluspleuropneumoniae (Ap) induced pleuropneumonia is increasing worldwide due to the reduction of antimicrobials use. Farms do not usually know which and how many serotypes are endemic to their farm or to replacement stock. On a continuous basis Ceva publishes successful Coglapix® challenge trials against new Ap serotypes and at the same time significant superiority towards major competitors. The same is encouraged at farm level as field trials for the dual purpose in supporting sales and supporting with local field data particularly on lung lesions scoring, antimicrobials use and ROI. A second focus is to increase awareness on not only the death losses due to per-acute and acute, but also the sub-acute manifestations.